Member Info for Spuddymadrid

Very happy to see this being mentioned: MRE upgrade during the current quarter. This I would say is directed toward RIO and other potential interested parties !!

happy new year to you swizz and makeabundle. thank you very much to both for your comments and updates. it is incredible how the greens and those who facilitated their entrance into government have been responsible for this **** sh0w. it is equally disgraceful that the courts allowed vevan hoover up barryroe/providence without consideration to the small shareholders. and all this because a zealot like ryan was allowed into the chicken koop.

Nobody is going to get 30m worth of shares in Hookipa at the silly present market rate. The shares will be issued at 2.81 dollars or close to that.

I was looking at Gileads list of drugs. They have a phase one metabolic GLP-1R GS-4571. Poolbeg had signed a strategic cooperation deal with a US Nasdaq Listed Pharma. Bet you it was Gilead. Gilead also have a bucket load of inflamatory medicines so would be very keen on Polb-001. There is alot more to this deal than meets the eye. CF may be smarter than the market is giving him credit for. Gilead wants Poolbeg in. I think we are now begining to see why !!!!

Hello Marc. My mistake. 2.25 which equates to 6.7 pence

Hello Jaxon. You will pay over the market value because you wont get 30m dollars worth of shares which would represent 27% of the company at the present silly low levels. Hookipa share sale volume is low. Put a bid into the market now for 30m dollars worth of shares and see what will happen to the offfer.

Hello Marc. 2.81 dollars would equate to 7 pence a share at an exchange rate of 1.20 sterling/dollar.

Hello Marc

My belief is that the raise will take place at the indicative 2,81 irrespective of the present share price. Gilead will at least maintain its 19% holding which would require around 14 m from their side. Gilead will not want to cross Hookipa nor Poolbeg share holders for a few pennies. I also believe that the CVRs might never be exercised in full. If Gilead likes what it sees going forward easier to buy the lot and use some of the funds destined for cvr milestone payments as part of takeover payment. Jmho

Hello Cash. Hope you are well. I am more confident about the merger. I think the raise will be completed at 2.81 irrespective of the present Hookipa share price. I think the Hoookipa price will also rebound in any case. Gilead will want to maintain their 19% overall share iof Hoikipa post merger. To do this I have calculated they would need to invest 14m out if the 30m raise. Once on the nasdaq we will have Gilead a 100bn plus market cap pharma as a major investor. I do not think we will be diluted more than the 40% post placement. This is a huge deal for us. Imagine if Gilead had started heavily investing in Poolbeg. Some are selling Poolbeg at the monent but these are only short term drops. The price will recover. I think many investors are making bad decisions out of fear. Poolbeg management should have explained things better for sure.

Absolutely silly to sell at these levels. The merger will go ahead, the placement by Hookipa will go ahead and the shares will rerate massively in the next 1-2 years

Hard to figure out what is going on. The share price of both companies do not mean much now . From the rns it says the money will be raised by a parallel placement at a 2024 weighted average price of 2.81 dollars once the combination of both companies is completed. It would be nice to know if the placement agreement has been signed off to have legally binding effect once the merger between Hookipa and Poolbeg completes. Gilead may be one of the investors along with CF and others. The figure of 2,81 was not just plucked from tje air I imagine. There must be some guaranteed that the money will be raised at 2.81 dollars as it is part of the overall deal !!

I think the problem here is the cash raise. Poolbeg need to tell investors whether the cash raise price that Hookipa will undertake has been agreed or not beforehand. If not then this is conpletely farcical and negligent. The same happened with a company callled Helium One where they informed the market in advance that they needed to raise cash and that drove the share price into the ground. It is hard to believe they could all be this stupid and not have agreed the price with potential new investors. If the raiise price has been agreed at the weighted average share price for last year (circa 2.74 was mentioned I believe) then the deal is a good one,

Hehe thank you Peterrr. Hopefully we will all have a good 2025. Regards

Novartis paid in excess of 1bn recently for a preclinical company - Kate. So i believe anything is possible. Not sure why Amryt team are onboard. But happy that they are,

https://www.biopharmadive.com/news/novartis-kate-gene-therapy-acquisition-duchenne-nervous-system/733613/

Hello there Trout. I get the feeling that the managment are lining Poolbeg up for a handsome buyout. Polb-001, Glp-1R, AI data et cetera,

Thanks for the update Marc. It is all about getting the right deal now. Take care

And here is an article that discusses how useful AI is for drug discovery Peterrr.

https://www.sciencedirect.com/science/article/pii/S266732582400205X

No Christmas cards received my end Peterr. I am still confident anf believe these things take time as I said before. I am not happy with the share price and as we all know a good deal will have us all smiling

Hello there HallsWorthy. I can see where you are coming from and understand your frustration. I have held my shares since early 2023. You may find it hard to believe but I am very optimistic on POlb-001. I believe it is a gem and that the right deal will be done as opposed to a bad deal made just to play to the gallery. The individuals connected with this company aside from the management are top notch - Luke o Neil, Brendan Buckley et cetera. This will work out well for all shareholders including yourself. I am impatient and want to see deals done but am confident of good news ahead.

Https://www.share-talk.com/top-12-small-cap-stocks-to-watch-in-2025-part-2-kod-mnrg-neo-ondo-polb-ree/